[go: up one dir, main page]

SV2006002192A - Amidas del acido 5 y 6-aminoalquil indol-2-carboxilico 3-sustituidas y analogos relacionados como inhibidores de la caseina cinasa ie - Google Patents

Amidas del acido 5 y 6-aminoalquil indol-2-carboxilico 3-sustituidas y analogos relacionados como inhibidores de la caseina cinasa ie

Info

Publication number
SV2006002192A
SV2006002192A SV2005002192A SV2005002192A SV2006002192A SV 2006002192 A SV2006002192 A SV 2006002192A SV 2005002192 A SV2005002192 A SV 2005002192A SV 2005002192 A SV2005002192 A SV 2005002192A SV 2006002192 A SV2006002192 A SV 2006002192A
Authority
SV
El Salvador
Prior art keywords
formula
inhibitors
aminoalquil
caseina
cinasa
Prior art date
Application number
SV2005002192A
Other languages
English (en)
Inventor
William Arthur Metz Jr
Fa-Xiang Ding
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Publication of SV2006002192A publication Critical patent/SV2006002192A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

SE DESCRIBE Y REIVINDICA COMPUESTOS DE FORMULA (I) Y FORMULA (II) (VER FORMULA) COMO INHIBIDORES DE LA CASEINA IE HUMANA, Y METODOS DE USO DE DICHOS COMPUESTOS DE FORMULA (I) Y FORMULA (II) PARA EL TRATAMIENTO DE ENFERMEDADES Y TRASTORNOS DEL SISTEMA NERVIOSO CENTRAL INCLUYENDO TRASTORNOS DEL ESTADO DE ANIMO Y TRASTORNOS DEL SUEÑO. TAMBIEN SE DESCRIBEN Y REIVINDICAN COMPOSICIONES FARMACEUTICAS QUE COMPRENDE COMPUESTOS DE FORMULA (I) O FORMULA (II) .
SV2005002192A 2004-08-19 2005-08-10 Amidas del acido 5 y 6-aminoalquil indol-2-carboxilico 3-sustituidas y analogos relacionados como inhibidores de la caseina cinasa ie SV2006002192A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US60338004P 2004-08-19 2004-08-19

Publications (1)

Publication Number Publication Date
SV2006002192A true SV2006002192A (es) 2006-06-28

Family

ID=35311279

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2005002192A SV2006002192A (es) 2004-08-19 2005-08-10 Amidas del acido 5 y 6-aminoalquil indol-2-carboxilico 3-sustituidas y analogos relacionados como inhibidores de la caseina cinasa ie

Country Status (26)

Country Link
US (2) US7629376B2 (es)
EP (1) EP1794122B1 (es)
JP (1) JP4843608B2 (es)
KR (2) KR20070043012A (es)
CN (1) CN101006055B (es)
AR (1) AR050919A1 (es)
AT (1) ATE508112T1 (es)
AU (1) AU2005277523B2 (es)
BR (1) BRPI0514380A (es)
CA (1) CA2577667C (es)
DE (1) DE602005027858D1 (es)
GT (1) GT200500214A (es)
IL (1) IL181156A (es)
JO (1) JO2724B1 (es)
MA (1) MA28863B1 (es)
MX (1) MX2007001382A (es)
NO (1) NO20071466L (es)
NZ (1) NZ552800A (es)
PA (1) PA8642901A1 (es)
PE (1) PE20060498A1 (es)
RU (1) RU2369599C2 (es)
SV (1) SV2006002192A (es)
TW (1) TWI357897B (es)
UY (1) UY29078A1 (es)
WO (1) WO2006023467A1 (es)
ZA (1) ZA200700651B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9018238B2 (en) 2009-02-12 2015-04-28 Pharmadesign, Inc. Inhibitor of casein kinase 1δ and casein kinase 1ε
WO2010121225A2 (en) * 2009-04-17 2010-10-21 Cylene Pharmaceuticals, Inc. Method of treating disorders associated with protein kinase ck2 activity
CN104540831B (zh) 2012-06-27 2017-11-07 4Sc探索有限责任公司 用于治疗癌症、自身免疫性炎症和cns紊乱的二氟二氧戊环‑氨基‑苯并咪唑激酶抑制剂
CN111757879A (zh) 2018-01-29 2020-10-09 卡地拉健康护理有限公司 用作抗菌剂的杂环化合物
WO2022006377A2 (en) * 2020-07-02 2022-01-06 Mbq Pharma Heterocyclic inhibitors of rho gtpases for the treatment of disease
US12209078B2 (en) 2021-10-06 2025-01-28 Mbq Pharma Crystalline forms of carbazole inhibitors of RhoGTPase for the treatment of disease

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5296471A (en) 1992-12-22 1994-03-22 Glycomed Incorporated Method for controlling o-desulfation of heparin and compositions produced thereby
IL146729A0 (en) * 1999-06-08 2002-07-25 Aventis Pharma Inc Screening methods for altering circadian rhythm proteins
WO2001083472A1 (en) * 2000-04-28 2001-11-08 Acadia Pharmaceuticals, Inc. Muscarinic agonists
CA2494962C (en) * 2002-08-09 2011-06-14 Merck & Co., Inc. Tyrosine kinase inhibitors
US7402672B2 (en) * 2003-12-11 2008-07-22 Aventis Pharmaceuticals Inc. Substituted 1H-pyrrolo[3,2-b, 3,2-c, and 2,3-c]pyridine-2-carboxamides and related analogs as inhibitors of casein kinase lepsilon

Also Published As

Publication number Publication date
TWI357897B (en) 2012-02-11
CN101006055B (zh) 2011-06-22
NZ552800A (en) 2010-11-26
ATE508112T1 (de) 2011-05-15
BRPI0514380A (pt) 2008-06-10
HK1105196A1 (en) 2008-02-06
GT200500214A (es) 2006-03-27
US7629376B2 (en) 2009-12-08
EP1794122A1 (en) 2007-06-13
IL181156A0 (en) 2007-07-04
AR050919A1 (es) 2006-12-06
JP2008510017A (ja) 2008-04-03
JP4843608B2 (ja) 2011-12-21
PE20060498A1 (es) 2006-07-10
ZA200700651B (en) 2008-09-25
US7923466B2 (en) 2011-04-12
US20090082340A1 (en) 2009-03-26
JO2724B1 (en) 2013-09-15
AU2005277523A1 (en) 2006-03-02
NO20071466L (no) 2007-04-19
MA28863B1 (fr) 2007-09-03
CN101006055A (zh) 2007-07-25
RU2007109783A (ru) 2008-09-27
AU2005277523B2 (en) 2011-09-29
UY29078A1 (es) 2006-03-31
WO2006023467A1 (en) 2006-03-02
CA2577667A1 (en) 2006-03-02
PA8642901A1 (es) 2006-05-16
DE602005027858D1 (de) 2011-06-16
CA2577667C (en) 2011-01-04
IL181156A (en) 2011-09-27
RU2369599C2 (ru) 2009-10-10
MX2007001382A (es) 2007-04-19
US20080027124A1 (en) 2008-01-31
EP1794122B1 (en) 2011-05-04
KR20070043012A (ko) 2007-04-24
TW200621711A (en) 2006-07-01
KR20130038409A (ko) 2013-04-17

Similar Documents

Publication Publication Date Title
PA8675701A1 (es) Nuevos derivados del fluoreno, composiciones que los contienen y su utilización
GT200600193A (es) Imidazoquinolines como inhibidores de lipidos kinase
CU23464B7 (es) (1,8)naftidirin-2-onas y compuestos relacionados para el tratamiento de la esquizofrenia
UY28482A1 (es) Nuevos compuestos
ECSP055676A (es) Piperazinas heterocíclicas sustituidas para el tratamiento de la esquizofrenia
CL2008003096A1 (es) Compuestos derivados de piperidino-dihidrotienopirimidinas; inhibidores pde4; composicion farmaceutica que los comprende; y uso en el tratamiento de trastornos o enfermedades de las vias respiratorias o gastrointestinales, como tambien enfermedades inflamatorias de las articulaciones u ojos, entre otras.
ECSP088283A (es) Compuestos de piridina 5- (fenilisoxazoliletoxi) -triazol- 3-ilo substituidos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor
ATE417610T1 (de) Zusammensetzung enthaltend 6-ä3-(1-adamantyl)-4- methoxyphenylü-2-naphthanoesäure zur behandlung dermatologischer erkrankungen
ECSP055536A (es) Derivados de 1-heterociclilalquil-3-sulfonilindol o indazol como ligandos de 5-hidroxitriptamina-6
ECSP077421A (es) Compuestos y composiciones como inhibidores de la actividad del receptor canabinoide 1
ECSP055535A (es) Derivados de 1-heterociclialquil-3-sulfonilazaindol o azaindol como ligandos de 5-hidroxitriptamina-6
SV2009003212A (es) Inhibidores de metaloproteasa derivados de heterociclicos ref. prd2727svpct
BRPI0418099A (pt) compostos, composição farmacêutica, e uso de um composto
UY29079A1 (es) Acidos fenoxiacéticos sustituidos, composiciones que los contienen, procedimientos de preparación y aplicaciones
ECSP045353A (es) Derivados de benzoxazinona, su preparación y aplicación como medicamentos
UY29223A1 (es) Ácidos fenoxiacéticos sustituidos, composiciones farmacéuticas que los contienen y procesos para su preparación
MX376743B (es) Síntesis de lactonas de ácido resorcílico útiles como agentes terapéuticos
UY29414A1 (es) Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos
SV2006002190A (es) Amidas sustituidas de acido tienopirrolcarboxilico, amidas del acido pirrolotiaxolcarboxilico y analogos relacionados como inhibidores de la caseina cinasa ie
UY27998A1 (es) Piperazinas sustituidas sustituidas heterocíclicas para el tratamiento de la esquizofrenia
DOP2003000587A (es) AGONISTAS DEL RECEPTOR ß3-ADRENERGICO
SV2006002192A (es) Amidas del acido 5 y 6-aminoalquil indol-2-carboxilico 3-sustituidas y analogos relacionados como inhibidores de la caseina cinasa ie
CR7735A (es) Piperizinas heterociclicas sustituidas para el tratamiento de la esquizofrenia
BRPI0507745A (pt) compostos de azetidina substituìda como inibidores de ciclooxigenase-1-ciclooxigenase-2, processo para a sua preparação, medicamentos e seus usos
DOP2005000157A (es) Amidas del acido 5 y 6-aminoalquil indol-2-carboxilico 3-sustituidas y analogos relacionados como inhibidores de la caseina cinasa 1

Legal Events

Date Code Title Description
FG Grant